Related Experiment Videos
Detection of experimental hepatic tumors using long circulating superparamagnetic particles
Y Sayegh1, S Pochon, J P Vallée
1Départment de Radiologie, H pital Universitaire de Genéve, Switzerland.
Investigative Radiology
|February 15, 2001
Summary
An iron oxide-based MR contrast agent effectively detects early liver tumors by enhancing tumor-to-liver contrast. This superparamagnetic blood pool agent (SBPA) improves tumor delineation during the vascular phase.
Area of Science:
- Magnetic Resonance Imaging (MRI)
- Medical Imaging
- Nanotechnology
Background:
- Early detection of liver tumors is crucial for effective treatment.
- Iron oxide nanoparticles are being explored as contrast agents in MRI.
- Superparamagnetic blood pool agents (SBPA) offer unique properties for vascular imaging.
Purpose of the Study:
- To evaluate an iron oxide-based MR contrast agent for detecting experimental liver tumors.
- To assess the agent's efficacy during the early vascular phase of tumor perfusion.
- To determine the agent's impact on tumor-to-tissue contrast.
Main Methods:
- Superparamagnetic blood pool agent (SBPA) administered intravenously to rabbits with VX2 liver tumors.
- MRI scans acquired before, immediately after, and weeks post-injection.
- Signal intensity variations measured in tumors and tissues using various MRI sequences.
Main Results:
- SBPA enabled detection of 14/16 and 12/16 tumors immediately post-injection using T2-weighted fast spin-echo and gradient-recalled-echo sequences, respectively.
- Significant signal intensity decrease observed in well-perfused organs, with blood signal abolished.
- Enhanced tumor-to-liver and tumor-to-blood contrast achieved during the vascular phase.
Conclusions:
- The dominant T2 effect of SBPA significantly improves liver tumor detection and delineation.
- SBPA allows distinction between small lesions and vessels.
- The contrast enhancement effect persists for days due to SBPA incorporation into the reticuloendothelial system.